Member Info for Chrisatrdg

Update on Summit website today:

On June 27, 2018, Summit announced the top line data from PhaseOut DMD, a Phase 2 proof of concept trial evaluating the small molecule utrophin modulator, ezutromid.
A letter to the DMD Community was published and a copy of this can be found below.
hTtps://www.summitplc.com/programmes/duchenne-muscular-dystrophy/
Edit: Looks pretty final to me not a mention of other drugs in the 'pipeline'.

I have just topped up a further 2,500 at 41.80 total cost excl. charges £1,045 I just hope that I have not totally lost the plot.GLA.

I have just noted a second 1.3m Buy at 45p value £585k clearly someone Buying at these bargain prices considering underlying value of company.I have topped up 10,000 shares today (post my earlier comments)at an average of 51p by selling my SAR & PYC shares at a small profit in order to have a small average down but no more.Hopefully there will be a SP rise in the morning.

I agree with you Latino those were my thoughts having listened earlier this afternoon.
Per waterloo01 from the other board & based on his thoughts I can see a some SP recovery :
'A very bad day for the company and it's shareholders regardless and no doubt the duel listing will initially work against us (The US knows little of the antibiotic work), but with a rational rather than emotional 'hat on' a £30m market cap is an opportunity as they have almost that in cash, a phase 3 ready and mainly grant funded to the tune of $62m and have recently bought Discuva and have an excellent looking further antibiotic against gonorrhoea.
That's my rational take on it.'

You do not make todays appointments unless it is 'Game on'.Onwards and Upwards.Clearly a Strong Buy.

Looking at the current SP I think people are getting the message.

You are so correct Del77 there was talk of the £1 party pre consolidation & yes that now means £20 but not sure that will be the case until Summit are manufacturing the DMD drug etc.However I think the 25p party may be around the corner i.e. £5.

I am now looking forward to the next Red Dot when Valirx announce a deal & the SP will then rocket hopefully soon.Current SP is still 'cheap as chips'.

Thanks Ollieh a great post & interesting reading.

Hi synergy3 I do not think there have been any posts since mine all very quite here more activity on the other board.

Physiomics PLC@Physiomics 1h1 hour ago More BBC News - Artificial intelligence can be weapon in cancer fight, PM to say

Thanks Dana I have always believed in the project & thanks for all you have done.Regards

Well done INFA Friday will be interesting based on the late surge today I will soon be in profit at this rate .Onwards & upwards.Clearly now a strong Buy.

Totally agree mcadder !!!

I am hoping that todays SP movement is news filtering through as to how good an investment PYC could be - Is todays SP about to blow upwards.I hope so.

Sareum Holdings plc@Sareumplc48m48 minutes ago $SAR.L Sareum Holdings pleased as Sierra Oncology advances cancer drug SRA737 combination trial into Phase 2 http://tinyurl.com/yadcuy6r via @proactive_uk @Sareumplc #AIM #biotech #Chk1 To move onto Phase 2 is great news clearly recognised stateside yesterday not yet on AIM.Onwards & upwards

Hi Del77 I support your 300p but not sure by board meeting in June but with positive news on DMD it will surely go to 300p & more.I sold some shares on 28/01 at 2.40 & currently have a further number of shares out at 300p in anticipation of positive news in Qtr 3.

ValiRx plc � Notice of Annual General Meeting 2018 - link clearly shows 6 & 7 which have been withdrawn for those requesting a copy: http://www.valirx.com/investor-relations/general-meetings-documentation/

AGM RNS The Annual General Meeting will be held at 10:00am BST on Thursday, 7 June 2018 at Wax Chandlers' Hall, 6 Gresham Street, London, EC2V 7AD. UK. http://otp.investis.com/clients/uk/summit_corporation_plc/rns/regulatory-story.aspx?newsid=1005575&cid=1575 I will be going anyone else?

Summit tweet this morning: The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy https://www.tandfonline.com/doi/abs/10.1080/21678707.2018.1438261